Nuveen Asset Management LLC Sells 42,360 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Nuveen Asset Management LLC lessened its holdings in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 32.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 87,506 shares of the company's stock after selling 42,360 shares during the quarter. Nuveen Asset Management LLC owned about 0.23% of Entrada Therapeutics worth $1,513,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS purchased a new position in Entrada Therapeutics during the 4th quarter valued at approximately $36,000. BNP Paribas Financial Markets purchased a new position in Entrada Therapeutics during the 4th quarter valued at approximately $57,000. Virtus ETF Advisers LLC purchased a new position in Entrada Therapeutics during the 4th quarter valued at approximately $68,000. AlphaQuest LLC purchased a new position in Entrada Therapeutics during the 4th quarter valued at approximately $70,000. Finally, Russell Investments Group Ltd. grew its holdings in Entrada Therapeutics by 53,455.6% during the 4th quarter. Russell Investments Group Ltd. now owns 4,820 shares of the company's stock valued at $83,000 after buying an additional 4,811 shares in the last quarter. Institutional investors own 86.39% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Entrada Therapeutics in a report on Tuesday, May 20th.

Entrada Therapeutics Stock Up 2.4%

TRDA traded up $0.19 during trading hours on Thursday, reaching $8.12. 107,234 shares of the company's stock traded hands, compared to its average volume of 132,648. Entrada Therapeutics, Inc. has a 52-week low of $7.10 and a 52-week high of $21.79. The firm has a market capitalization of $308.18 million, a PE ratio of 5.11 and a beta of 0.04. The firm has a 50-day moving average price of $8.25 and a 200 day moving average price of $12.48.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.36. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The business had revenue of $8.75 million during the quarter, compared to analysts' expectations of $10.98 million. Equities analysts predict that Entrada Therapeutics, Inc. will post 1.12 EPS for the current fiscal year.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.